Calamos Advisors LLC Acquires Shares of 19,479 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Calamos Advisors LLC purchased a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,479 shares of the company's stock, valued at approximately $1,205,000.

Several other hedge funds have also modified their holdings of AMPH. Jacobs Levy Equity Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 44.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company's stock valued at $25,518,000 after purchasing an additional 171,642 shares during the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Amphastar Pharmaceuticals by 1,561.9% during the third quarter. Qube Research & Technologies Ltd now owns 102,324 shares of the company's stock valued at $4,706,000 after purchasing an additional 96,167 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Amphastar Pharmaceuticals by 52.2% during the third quarter. American Century Companies Inc. now owns 200,277 shares of the company's stock valued at $9,211,000 after purchasing an additional 68,668 shares during the last quarter. Moody Aldrich Partners LLC bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at approximately $3,904,000. Finally, Mesirow Institutional Investment Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 42.0% during the third quarter. Mesirow Institutional Investment Management Inc. now owns 183,805 shares of the company's stock valued at $8,453,000 after purchasing an additional 54,343 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Trading Up 0.4 %

AMPH traded up $0.16 during mid-day trading on Monday, hitting $40.17. The stock had a trading volume of 345,088 shares, compared to its average volume of 462,217. The stock's fifty day simple moving average is $45.96 and its 200-day simple moving average is $51.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 15.57, a price-to-earnings-growth ratio of 0.95 and a beta of 0.85. Amphastar Pharmaceuticals, Inc. has a 1-year low of $35.62 and a 1-year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). The firm had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. As a group, research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.43 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Michael A. Zasloff sold 12,500 shares of the firm's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at $1,006,160.68. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Floyd F. Petersen sold 500 shares of the firm's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total value of $26,550.00. Following the completion of the transaction, the director now owns 80,333 shares of the company's stock, valued at $4,265,682.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael A. Zasloff sold 12,500 shares of the business's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at $1,006,160.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,000 shares of company stock worth $660,860. Company insiders own 27.10% of the company's stock.

Analysts Set New Price Targets

AMPH has been the topic of several analyst reports. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They issued an "overweight" rating and a $60.00 price objective on the stock. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, February 29th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $66.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.